Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;5(9):e1552.
doi: 10.1002/cnr2.1552. Epub 2022 Apr 28.

Treatment outcomes of T and natural-killer/T-cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy

Tricia Tay  1 , Nagavalli Somasundaram  1 , Cindy Lim  2 , Lay Poh Khoo  1 , Allan Zhi Kai Goh  3 , Yuh Shan Lee  3 , Xin Liu  4 , Miriam Tao  1 , Richard Quek  1 , Mohamad Farid  1 , Eileen Poon  1 , Jason Y S Chan  1 , Esther W Y Chang  1 , Valerie S W Yang  1 , Yeow Tee Goh  3 , Daryl Tan  3 , Colin Diong  3 , Nicholas F Grigoropoulos  3 , Chandramouli Nagarajan  3 , Michelle Poon  4 , Sanjay de Mel  4 , Anand Jeyasekharan  4 , Esther H L Chan  4 , Joanne Lee  4 , Yen Lin Chee  4 , Soon Thye Lim  1 , Tiffany Tang  1
Affiliations

Treatment outcomes of T and natural-killer/T-cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy

Tricia Tay et al. Cancer Rep (Hoboken). 2022 Sep.

Abstract

Background: Contemporary data of peripheral T-cell lymphoma (PTCL) and natural-killer/T-cell lymphoma (NKTL) patients treated with ifosfamide, carboplatin and etoposide (ICE) are limited.

Aims: We performed a retrospective analysis to estimate outcomes of ICE-treated PTCL and NKTL patients at three tertiary cancer centres in Singapore.

Methods and results: Patients were identified through lymphoma databases from National Cancer Centre Singapore (NCCS), National University Hospital, Singapore (NUHS), and Singapore General Hospital (SGH). Responses and survival outcomes were determined from electronic medical records. A total of 75 patients with a median age of 50 were included. ICE was used as first-line treatment in 14 patients (19%) and as subsequent lines of treatment in 61 patients (81%). The overall response rates (ORR) for all patients was 63% (40% complete response [CR]). The ORR and CR in the first line were 86% and 64% respectively. At a median follow-up duration of 71.0 months, the median progression-free (PFS) and overall survival (OS) for all patients were 4.4 months (95%CI, 2.7-6.0) and 16 months (95%CI, 8.3-45.4) respectively.

Conclusion: In summary, ICE showed high ORR but poor PFS in relapsed/refractory PTCL and NKTL. ORR of ICE in the first line setting appears better than real-world CHOP data and warrants further study.

Keywords: Asia; T-cell lymphoma; chemotherapy; haematology-oncology; natural-killer/T-cell lymphoma.

PubMed Disclaimer

Conflict of interest statement

The authors have stated explicitly that there are no conflicts of interest in connection with this article.

References

    1. Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T‐cell phenotype in aggressive non‐Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood. 1998;92(1):76‐82. - PubMed
    1. Melnyk A, Rodriguez A, Pugh WC, Cabannillas F. Evaluation of the revised European‐American Lymphoma Classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non‐Hodgkin's lymphoma ‐ PubMed. Blood. 1997;89(12):4514‐4520. - PubMed
    1. Vose JM, Neumann M, Harris ME, Armitage J, Weisenburger D. Interantional T‐cell lymphoma project. International peripheral T‐cell and natural killer/T‐cell lymphoma study: pathology findings and clinical outcomes international T‐cell lymphoma project. J Clin Oncol. 2008;26(25):4124‐4130. - PubMed
    1. Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T‐cell lymphoma, nasal type: the NK‐cell tumor study group study. J Clin Oncol. 2011;29(33):4410‐4416. - PubMed
    1. Kwong YL, Kim WS, Lim ST, et al. SMILE for natural killer/T‐cell lymphoma: analysis of safety and efficacy from the Asia lymphoma study group. Blood. 2012;120(15):2973‐2980. - PubMed